May 16, 2017 / 9:36 AM / 3 months ago

BRIEF-4SC intends to raise new capital

May 16 (Reuters) - 4SC AG:

* ANNOUNCED AN UPDATED DEVELOPMENT PLAN AND INTENTION TO RAISE NEW CAPITAL TO FUND FURTHER DEVELOPMENT OF 4SC'S LEAD DRUG CANDIDATES RESMINOSTAT, 4SC-202 AND 4SC-208 UNTIL EARLY 2020

* TO THIS END, IN 2017, 4SC INTENDS BOTH TO INITIATE A PHASE II STUDY IN PATIENTS WITH ADVANCED MELANOMA AND TO SUPPORT A FURTHER PHASE II STUDY IN PRE-TREATED PATIENTS WITH MICROSATELLITE-STABLE GASTROINTESTINAL CANCERS

* PLANS COMPLETE FORMAL PRECLINICAL DEVELOPMENT OF 4SC-208 WITH AIM OF STARTING PHASE I/II CLINICAL TESTING IN EARLY 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below